Finoriq research workspace
Aldeyra Therapeutics, Inc. (ALDX) SEC Filings & Filing Highlights
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to. Review ALDX SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
- Company
- Aldeyra Therapeutics, Inc. (ALDX)
- Ticker
- ALDX
- Market Cap
- $104.1M
- Latest Price
- $1.725
- Industry
- Biotech & Pharma
Aldeyra Therapeutics, Inc. (ALDX) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Aldeyra Therapeutics, Inc. (ALDX).
| Event | Form | Date |
|---|---|---|
| Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of DirectorsAldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors | 8-K7.01 | 2026-06-10 |
| At the 2026 Annual Meeting held on June 9, 2026, the following proposals were submitted to the...At the 2026 Annual Meeting held on June 9, 2026, the following proposals were submitted to the stockholders of the Company | 8-K5.07 | 2026-06-10 |
| (d) On June 9, 2026, following Aldeyra Therapeutics, Inc.’s (the “Company”) 2026 annual meeting...(d) On June 9, 2026, following Aldeyra Therapeutics, Inc.’s (the “Company”) 2026 annual meeting of stockholders (the “2026 Annual Meeting”)... | 8-K5.02 | 2026-06-10 |
| Innovative Therapeuticsfor Immune-Mediated Diseases CORPORATE OVERVIEW May 2026 Nasdaq: ALDX ©...Innovative Therapeuticsfor Immune-Mediated Diseases CORPORATE OVERVIEW May 2026 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2026 Exhibit 99.1 | 8-K7.01 | 2026-05-01 |
| (b) On April 20, 2026, Martin J. Joyce, a member of the Board of Directors of Aldeyra Therapeut...(b) On April 20, 2026, Martin J. Joyce, a member of the Board of Directors of Aldeyra Therapeutics, Inc. (“Aldeyra”), notified Aldeyra of h... | 8-K5.02 | 2026-04-20 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.